New York, United States | April 29, 2026
Pfizer Inc. has reported positive Phase 3 clinical trial results for ELREXFIO, demonstrating a statistically significant and clinically meaningful improvement in progression-free survival (PFS) in patients with relapsed or refractory multiple myeloma (RRMM). The results from the MagnetisMM-5 study represent a major advancement in oncology, reinforcing the clinical value of bispecific antibody immunotherapy in treating complex hematologic cancers.
Pfizer Phase 3 Study Demonstrates Strong Clinical Benefit
The MagnetisMM-5 Phase 3 trial achieved its primary endpoint, showing that patients receiving ELREXFIO monotherapy experienced significantly longer progression-free survival compared to those treated with standard-of-care regimens, including daratumumab, pomalidomide, and dexamethasone. The randomized, open-label, multicenter study enrolled 497 patients across 26 countries, all previously treated with at least one prior therapy such as lenalidomide and proteasome inhibitors.
Notably, the results exceeded the predefined interim efficacy threshold, indicating a strong and durable response. While overall survival (OS) data is still being evaluated, the trial continues, and the results are expected to support future regulatory submissions and label expansion strategies. These findings further strengthen Pfizer’s position in advancing innovative oncology therapeutics.
Consistent Safety Profile Supports Clinical Use
Advertisement
The safety analysis confirmed that ELREXFIO maintains a consistent and manageable safety profile, with no new safety concerns identified during the study. As a BCMA-CD3 bispecific antibody, the therapy activates T cells to target and eliminate myeloma cells, offering a highly specific immunotherapeutic mechanism.
Common risks include cytokine release syndrome (CRS) and neurological side effects, which are well-characterized in T-cell–engaging therapies. Patients undergo a controlled step-up dosing schedule, including initial hospitalization to monitor adverse events. The treatment is also governed by a Risk Evaluation and Mitigation Strategy (REMS) program, ensuring adherence to GxP-compliant safety protocols and regulatory requirements.
Advancing Treatment Landscape in Multiple Myeloma
Multiple myeloma remains a highly aggressive and incurable blood cancer, affecting over 187,000 patients globally each year. Despite advancements, many patients relapse and require multiple lines of therapy, with survival outcomes still limited.
The success of ELREXFIO in this Phase 3 study highlights its potential to transform treatment strategies, particularly in earlier lines of therapy. The drug is already approved in multiple countries, including the United States and European Union, for heavily pretreated patients. Ongoing studies within the MagnetisMM clinical program aim to expand its use as both a monotherapy and combination therapy, further enhancing its clinical utility.
The Pfizer ELREXFIO Phase 3 results represent a significant breakthrough in multiple myeloma treatment, demonstrating improved patient outcomes through advanced immunotherapy. With strong efficacy, a manageable safety profile, and ongoing clinical development, ELREXFIO is positioned to become a key therapy in the evolving oncology landscape, highlighting the importance of innovation in GxP-regulated clinical research and targeted therapies.
Source: Pfizer press release
